StudyManager Expands into China
StudyManager (Seattle, WA), a developer of CTMS and EDC solutions, reports they recently expanded operations into China. The company's two newest customers are the Chinese CROs TigerMed and DMS-Pharma.
“China is the next logical step for us,” said Bruce Schatzman, Founder and Chief Executive Officer of StudyManager. “Because the cost of paper trials in China is still very competitive, we believe our EDC solution is a great choice when Chinese CROs and sponsors don’t see the price/performance value offered by larger EDC providers.”
To accomadate Asian expansion, StudyManager opened a data center in Shanghai, from which Chinese companies can run its EDC/CTMS system in what it calls "a secure and compliant manner."
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
